Immune compositions in non-tumor- and tumor-bearing p21 ^CE and p21 ^WT mice . (A) Quantification of white blood cells, red blood cells, and platelets in non-tumor-bearing p21^WT and p21^CE mice at weeks 8 and 12; n = 3–4 mice/group. (B) Flow cytometry quantification of total monocytes, neutrophils, and Ly6Chi monocytes in blood of non-tumor-bearing p21^WT and p21^CE mice; n = 7–9 mice/group. (C) Flow cytometry quantification of monocytes, neutrophils, and macrophages in the spleens of 8–12 wk p21^WT and p21^CE non-tumor-bearing mice; n = 7–9 mice/group. (D and E) Flow cytometry quantification of myeloid cells in bone marrow and blood of tumor-bearing p21^CE and p21^WT mice; n = 6 mice/group. (F) Flow cytometry analyses of the number of monocytes, neutrophils, cDC2s, cDC1s, NK cells, NKT cells, and γδT cells in the pancreas of p21^CE and p21^WT mice bearing orthotopic KP-2 tumors; n = 6 mice/group. (G) Bar graphs showing the MFI of MHCI, CD206, MHCII, CD40, CD11b, CSF1R, PDL1, PDL2, CD80, CD86 in TAMs from p21^WT and p21^CE mice bearing orthotopic KP-2 tumors. Data were pooled from multiple independent experiments. n = 6 mice/group. All graphs are expressed as the mean ± SEM. *, P < 0.05. For comparisons between any two groups, the Student’s two-tailed t test was used.